To analyze the effect of insulin degludec/insulin aspart injection combined with metformin extended-release tablets on insulin resistance in patients with type 2 diabetes mellitus (T2DM).

T2DM patients were divided into control group and treatment group using a cohort method. The control group received oral metformin extended-release tablets (0.5 g, tid) and subcutaneous injections of insulin glargine injection (10 U, qd), while the treatment group received oral metformin extended-release tablets (0.5 g, tid) and subcutaneous injections of insulin degludec/insulin aspart injection (0.1-0.2 U·kg^-1·d^-1, evenly divided before breakfast and dinner). Both groups were treated for 12 weeks. The efficacy, blood glucose control [fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin A1c(HbA1c)], insulin function [fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR) and homeostasis model assessment-β (HOMA-β)]were compared, and safety was evaluated.

A total of 49 cases were enrolled in the treatment group and 51 cases in the control group. The overall effective rates in the treatment and control groups were 93.88% (46 cases/49 cases) and 80.39% (41 cases/51 cases), respectively, showing a statistically significant difference (P<0.05). After treatment, the fasting blood glucose levels in the treatment and control groups were (5.83±0.79) and (6.53±0.81) mmol·L^-1; the 2-hour postprandial blood glucose levels were (7.73±0.86) and (8.41±0.97) mmol·L^-1; HbA1c levels were (6.34±0.88)% and (6.80±0.92)%; FINS levels were (6.02±1.13) and (7.13±1.04) mU·L^-1; HOMA-IR values were 1.56±0.20 and 2.07±0.23; HOMA-β values were 51.67±3.18 and 47.06±3.31, respectively, with all differences being statistically significant (all P<0.05). The adverse drug reactions in the treatment group mainly included hypoglycemia, nausea, dizziness, and diarrhea, while the adverse drug reactions in the control group mainly included hypoglycemia and nausea. The incidence of adverse drug reactions was 10.20% (5 cases/49 cases) in the treatment group and 11.76% (6 cases /51 cases) in the control group, with no statistically significant difference (P<0.05).

The combination of insulin degludec/insulin aspart injection and metformin extended-release tablets can improve insulin resistance and regulate blood glucose levels in T2DM patients, with good safety profiles.